Background: Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease in the US. Understanding the epidemiology of NAFLD, with specific focus on individuals with hepatic fibrosis is important to guide healthcare resource planning.
| INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease in the US. 1, 2 The increasing prevalence of obesity, diabetes mellitus and metabolic syndrome all increase the risk of developing NAFLD. [3] [4] [5] While the majority of NAFLD patients do not progress to advanced fibrosis, cirrhosis and cirrhosis-related complications including hepatocellular carcinoma and end stage liver disease, the large burden of NAFLD is such that even a small proportion of patients developing cirrhosis will lead to a huge burden to the health care system. 2, 6 Understanding the burden of NAFLD, and in particular the burden of NAFLD patients with significant fibrosis is important to help guide resource planning for the healthcare system
given that those patients with significant fibrosis are the ones most likely to develop disease progression and complications. 7 However, while many serology-based and imaging-based methods for assessment of fibrosis are available, limitations in accurately assessing fibrosis using a single tool in a single setting remain. Using combination of different methodologies as well as longitudinal assessment with these tools may be more accurate, of more prognostic value, and cost-effective. [8] [9] [10] [11] Furthermore, while identifying NAFLD patients with advanced fibrosis (F3 or greater) is particularly important given that these patients carry significantly higher risk of disease progression to cirrhosis and cirrhosis-related complications, understanding the prevalence of the larger pool of patients with significant fibrosis (F2 or greater) is also helpful to more accurately understand the disease burden of NAFLD patients. In addition, while the field of NAFLD or anti-fibrotic therapeutics is currently lacking, future therapies are likely to target specific sub-populations of patients with F2 or greater disease and F3 or greater disease. Thus, our current study focused on the prevalence of predictors of both significant and advanced fibrosis among individuals with NAFLD. In addition, understanding risk factors for significant fibrosis or advanced fibrosis among NAFLD patients may help guide the development of risk stratification models to identify high risk patients early, so that preventative care can be implemented to mitigate the long-term risk of disease progression. Our current study specifically aims to estimate the burden of NAFLD in the US, with particular emphasis on understanding the prevalence of and predictors of significant fibrosis and advanced fibrosis among adults with NAFLD.
2 | ME TH ODS 
| Prevalence of advanced fibrosis in NAFLD patients
When assessing for advanced fibrosis (F3 or greater) using NFS score and FIB-4 score, 9.7% and 2.3% of NAFLD patients had NAFLD-SF, respectively (Table 1) (Table 2) .
When assessing for NAFLD-AF using FIB-4, no sex-specific differences were observed in odds of NAFLD-SF. Similar to NFS, increasing age was associated with increasing odds of NAFLD-AF in the FIB-4 model (OR 1.09, 95% CI 1.02-1.18, P < .02). However, no specific differences in odds of NAFLD-AF were observed by race/ ethnicity, BMI, presence of diabetes or presence of hypertension ( 14, [23] [24] [25] This huge burden of NAFLD is a public health concern as it not only affects the individual patient, but has significant implications on patient quality of life as well as significant economic impact of the health care system. 26, 27 A recent study estimated annual direct medical costs associated with NAFLD to be $103 billion in the US and €35 billion in Europe with the highest costs seen among older individuals with NAFLD. 26 This is particularly concerning given the expected continuing rising incidence of NAFLD as well as the continued ageing of this NAFLD population.
While the significant burden of NAFLD in the US and worldwide is alarming, it is also important to note that the individuals with highest risk of NAFLD-related complications are those with evidence of fibrosis. The assessment of fibrosis in NAFLD is challenging, but the availability of several non-invasive tools including serology-based scoring systems and imaging-based tools offers many options to improve the evaluation. 8, 9, 12, 19 Furthermore, several studies have demonstrated the cost-effectiveness of utilising combination of noninvasive tools to stage severity of liver disease among NAFLD patients to help with disease management as well as guide referral to sub-specialty care. 10, 11, 28 Our current study evaluated fibrosis staging using three commonly employed serology-based scoring systems-APRI, NFS and FIB-4. Our rationale for including all three scoring systems is 3-fold: 1. These are commonly employed assessment tools that can be easily implemented by sub-specialty clinics, but also by primary care clinics that can help guide need for referral to gastroenterologists/hepatologists; 2. All three scoring systems have different performance characteristics and we believe that it is important to demonstrate the variations in disease prevalence using 
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While not consistent across all methods of assessing fibrosis, it is important to highlight that an increased risk of NAFLD as well as increased risk of significant and advanced fibrosis was seen with increasing age and presence of metabolic syndrome components, including BMI ≥ 30 kg/m 2 , diabetes and hypertension. These observations further strengthen the evidence of the association of metabolic syndrome and NAFLD, and continue to emphasise the importance of optimising management of these risk factors to reduce risk of disease progression among NAFLD patients. 5, 8, 30, 31 However, it is also important to note that lack of obesity does not necessarily eliminate one's risk of NAFLD, and consideration of NAFLD should also occur in lean patients as well as those who do not meet the criteria for having metabolic syndrome. 15, [32] [33] [34] While the use of a large validated dataset, NHANES, allowed the estimation of NAFLD and NAFLD with advanced fibrosis prevalence in the US, limitations inherent to the study design and NHANES need to be acknowledged. The diagnosis of NAFLD was defined based on exclusion of other chronic liver diseases in addition to presence of metabolic syndrome, and this method was based partly on data provided from survey-based methods, which can be subject to recall bias or reporter bias. Furthermore, certain components of the metabolic syndrome definition are based on concurrent medication use, and potential misclassification of individuals on diabetes or hypertension medications for other reasons may have occurred. Given the cross-sectional nature of the study design, our current study only provides evidence of NAFLD and NAFLD with advanced fibrosis prevalence and can only establish associations with respect to risk predictions. No clear causation can be established with these data. Despite these limitations, we believe our study using the most recently updated NHANES dataset does provide important epidemiological observations regarding NAFLD in the US, particularly given the expectation that NAFLD will become the leading aetiology of chronic liver disease in the US in the near future.
In conclusion, our analyses of the most recent NHANES dataset highlight the major burden of NAFLD among US adults, estimating the prevalence of individuals with NAFLD and advanced fibrosis to be as high as 5 million adults. While not consistent across all our methods of assessing fibrosis, presence of metabolic syndrome risk factors such as obesity, diabetes and hypertension, appeared to increase the risk of NAFLD and to increase the risk of fibrosis among patients with NAFLD.
